Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C62482
http://purl.obolibrary.org/obo/NCIT_C62482
Preferred Name

Tigatuzumab
Definitions
A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A humanized agonistic monoclonal antibody directed against human tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2) with potential antitumor activity. Mimicking the natural receptor ligand TRAIL, tigatuzumab binds to TRAIL-R2, activating signal transduction pathways that may result in tumor cell apoptosis and a reduction in tumor growth. A member of the tumor necrosis factor (TNF) receptor family, TRAIL-R2, also known as DR5 (death receptor 5), is expressed on the surfaces of many types of malignant cells.
prefLabel
Tigatuzumab
label
Tigatuzumab
PDQ_Closed_Trial_Search_ID
489323
code
C62482
Has_Target
prefixIRI
NCIT:C62482
in_subset
Display_Name
Tigatuzumab
Preferred_Name
Tigatuzumab
FDA_UNII_Code
237GB6IDKO
Contributing_Source
CTRP
FDA
Maps_To
Tigatuzumab
CAS_Registry
918127-53-4
NCI_Drug_Dictionary_ID
489323
Legacy Concept Name
CS-1008
type
Is_Value_For_GDC_Property
subClassOf
PDQ_Open_Trial_Search_ID
489323
Semantic_Type
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
UMLS_CUI
C2973415
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display